{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:03:35Z","timestamp":1784253815742,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Neoadjuvant dual HER2 blockade combined with chemotherapy is the standard treatment approach for patients with high-risk early-stage or locally advanced HER2-positive breast cancer. However, the optimal chemotherapy backbone and the predictive value of systemic inflammatory biomarkers remain subjects of ongoing investigation. This study aimed to compare pathologic complete response (pCR) rates between neoadjuvant dose-dense doxorubicin\/cyclophosphamide followed by paclitaxel plus trastuzumab and pertuzumab (ddAC+THP) and docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP), and to evaluate the predictive performance of pretreatment inflammatory biomarkers. Materials and Methods: In this multicenter retrospective study, patients with HER2-positive breast cancer treated with neoadjuvant ddAC+THP or TCHP between 2019 and 2025 at three tertiary centers were evaluated. Pretreatment inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and hemoglobin, albumin, lymphocyte, and platelet (HALP) score, were calculated from baseline laboratory parameters. Receiver operating characteristic analyses were performed to determine optimal cutoff values, and logistic regression analyses were used to identify predictors of pCR. Results: A total of 197 patients were included, of whom 138 received ddAC+THP and 59 received TCHP. Overall, 125 patients (63.5%) achieved pCR. The pCR rate was numerically higher in the ddAC+THP group than in the TCHP group (65.2% vs. 59.3%), although the difference was not statistically significant (p = 0.431). Among the evaluated biomarkers, SIRI demonstrated the highest discriminatory performance for predicting pCR (AUC: 0.725, 95% CI: 0.652\u20130.797), followed by NLR (AUC: 0.673, 95% CI: 0.595\u20130.750). In multivariable analysis, hormone receptor positivity (OR: 0.291, 95% CI: 0.131\u20130.645; p = 0.002) and elevated SIRI (&gt;0.845) (OR: 0.088, 95% CI: 0.036\u20130.216; p &lt; 0.001) were independently associated with lower odds of achieving pCR. No significant difference in pCR was observed between treatment regimens across predefined subgroup analyses. Conclusions: Neoadjuvant ddAC+THP and TCHP achieved comparable pCR outcomes in patients with HER2-positive breast cancer. SIRI was independently associated with a lower likelihood of achieving pCR and showed acceptable discriminatory performance. These findings suggest that SIRI may represent an exploratory, readily available inflammatory biomarker for pCR risk stratification; however, prospective validation is required before clinical application.<\/jats:p>","DOI":"10.3390\/medicina62071370","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:55:59Z","timestamp":1784249759000},"page":"1370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-9383","authenticated-orcid":false,"given":"G\u00f6khan","family":"\u015eahin","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet K\u00fcr\u015fad","family":"Di\u015fli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Erciyes University, 38039 Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8210-0837","authenticated-orcid":false,"given":"Firat","family":"Sirvan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-7772","authenticated-orcid":false,"given":"Mustafa Murat","family":"M\u0131d\u0131k","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Evsan","family":"Boyraz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oben","family":"Belen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-0426","authenticated-orcid":false,"given":"Taha Koray","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9133-8602","authenticated-orcid":false,"given":"Ay\u015fe","family":"Nuransoy Cengiz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Erciyes University, 38039 Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-154X","authenticated-orcid":false,"given":"Fatih","family":"Ku\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Atat\u00fcrk Sanatorium Training and Research Hospital, 06290 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8868-988X","authenticated-orcid":false,"given":"S\u0131la","family":"G\u00f6kdere","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6180-713X","authenticated-orcid":false,"given":"Erdem","family":"G\u00f6ker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"\u00c7akar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-1049","authenticated-orcid":false,"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mevl\u00fcde","family":"\u0130nan\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Erciyes University, 38039 Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-9467","authenticated-orcid":false,"given":"Deniz Can","family":"G\u00fcven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-377X","authenticated-orcid":false,"given":"Hasan \u00c7a\u011fr\u0131","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae insights: Breast cancer, version 4.2023: Featured updates to the NCCN guidelines","volume":"21","author":"Gradishar","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1245\/s10434-011-2108-2","article-title":"Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer","volume":"19","author":"Kaufmann","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Mandjes","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40261-023-01291-6","article-title":"Anthracyclines versus no anthracyclines in the neoadjuvant strategy for HER2+ breast cancer: Real-world evidence","volume":"43","author":"Luz","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.21037\/atm-22-4030","article-title":"Neoadjuvant therapy with vs. without anthracyclines for HER2-positive breast cancer: A systematic review and meta-analysis","volume":"11","author":"Zhu","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2337729","DOI":"10.1080\/07853890.2024.2337729","article-title":"Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: A meta-analysis","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2535091","DOI":"10.1080\/09581596.2025.2535091","article-title":"Association between systemic immune-inflammatory biomarkers (SII, NLR, PLR, LMR) and breast cancer","volume":"35","author":"Wen","year":"2025","journal-title":"Crit. Public Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12094-017-1732-0","article-title":"Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy","volume":"20","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1111\/jcmm.14934","article-title":"Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy","volume":"24","author":"Chen","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00129804-200311000-00004","article-title":"Chemotherapy-induced secondary malignancies","volume":"26","year":"2003","journal-title":"J. Infus. Nurs."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: A secondary analysis of the TRAIN-2 randomized, phase 3 trial","volume":"7","author":"Mandjes","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s13402-021-00634-9","article-title":"The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities","volume":"44","author":"Mehraj","year":"2021","journal-title":"Cell. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: Neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu\u2013positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCMA.0000000000001034","article-title":"Preoperative systemic inflammation response index: Clinicopathologic predictor of pathological complete response in HER2-positive breast cancer patients receiving neoadjuvant systemic therapy","volume":"87","author":"Wu","year":"2024","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chen, X., Cai, Q., Deng, L., Chen, M., Xu, M., Chen, L., Lin, Y., Li, Y., Wang, Y., and Chen, H. (2024). Association of inflammatory blood markers and pathological complete response in HER2-positive breast cancer: A retrospective single-center cohort study. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1465862"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/cncr.30057","article-title":"A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy","volume":"122","author":"Qi","year":"2016","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13643-025-02847-7","article-title":"Prognostic and clinicopathological impact of systemic inflammation response index (SIRI) on patients with esophageal cancer: A meta-analysis","volume":"14","author":"Wu","year":"2025","journal-title":"Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Birsin, Z., Nazl\u0131, \u0130., Alkan, O., Odaba\u015f\u0131 B\u00fck\u00fcn, H., G\u00fcnalt\u0131l\u0131, M., \u00c7erme, E., Aliyev, V., Cebeci, S., Jeral, S., and Abbasov, H. (2025). Inflammatory and Nutritional Markers Predicting Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Multicenter Real-World Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14207271"},{"key":"ref_30","first-page":"1277","article-title":"CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy","volume":"28","year":"2026","journal-title":"Clin. Transl. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ran, R., Zhao, S., Zhou, Y., Hang, X., Wang, H., Fan, Y., Zhang, Y., Qiao, Y., Yang, J., and Dong, D. (2024). Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: A retrospective study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12974-4"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10147-022-02115-x","article-title":"The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: A population-based study","volume":"27","author":"Han","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_33","first-page":"178","article-title":"Real-World Pathologic Complete Response Rates with Neoadjuvant Pembrolizumab in Stage II\u2013III Triple-Negative Breast Cancer: Impact of Ki-67 Proliferation Index","volume":"35","author":"Sahin","year":"2025","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Angelico, G., Broggi, G., Tinnirello, G., Puzzo, L., Vecchio, G.M., Salvatorelli, L., Memeo, L., Santoro, A., Farina, J., and Mul\u00e9, A. (2023). Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: A review of current evidence and prognostic implications from pathologist\u2019s perspective. Cancers, 15.","DOI":"10.20944\/preprints202306.0507.v1"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e11647","DOI":"10.1097\/MD.0000000000011647","article-title":"Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy","volume":"97","author":"Ryu","year":"2018","journal-title":"Medicine"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:22:05Z","timestamp":1784251325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medicina62071370"],"URL":"https:\/\/doi.org\/10.3390\/medicina62071370","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}